6th Age-Related Disease Therapeutics Summit

In 2024, age-related disease biotechs are set to shine, building on 2023's milestones such as Eli Lilly's partnership with BioAge to test muscle rejuvenation therapy and Chan Zuckerberg Biolabs tapping into immune cell engineering to eradicate age-related diseases.

To successfully navigate the volatile market of 2024, rapid proof-of-concept studies and validated clinical endpoints are crucial for funding and pipeline progress.

The 6th Age-Related Disease Therapeutics Summit is returning to San Francisco in June, with 60+ participants including Eli Lilly, Takeda, and Turn Biosciences to dive deep into breakthroughs in cellular programming, senolytic pathways, and epigenetic effects. Explore biomarkers, navigate regulations, and foster collaborations for pipeline support and commercialization.

This is your definitive age-related disease therapeutics forum to gain unparalleled competitive intelligence, scientific advancements and form meaningful partnerships to solve humankind's fundamental problem.

URLs:
Website: https://go.evvnt.com/2248550-0?pid=10018
Tickets: https://go.evvnt.com/2248550-2?pid=10018
Brochure: https://go.evvnt.com/2248550-3?pid=10018

Prices:
Conference + 2 Workshops - Drug Developer Pricing: USD 3797.00,
Conference + 1 Workshop - Drug Developer Pricing: USD 3398.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + 2 Workshops - Solution Provider Pricing: USD 4631.00,
Conference + 1 Workshop - Solution Provider Pricing: USD 4166.00,
Conference Only - Solution Provider Pricing: USD 3699.00

Speakers: Abdulkader Rahmo, President and CSO, SMS Biotech, AndAndrew Butler, Professor, Department of Pharmacology and Physiology, Institute for Translational Neuroscience, Saint Louis University School of Medicine, Christin Glorioso, Chief Executive Officer, NeuroAge Therapeutics, Corina Amor, Vegas Assistant Professor, Cold Spring Harbor Laboratory, Faizan Zubair, Principal Scientist, Takeda, Jesse Poganik, Instructor in Medicine, Harvard Medical School, Joseph Rodgers, Founder and Head of Biology, Fountain Therapeutics, Karl Pfleger, Investor, Founder, AgingBiotech.info, Katharine Grabek, Chief Scientific Officer, Fauna Bio, Kennedy Schaal, Chief Executive Officer, Rejuve Biotech, Maddalena Adorno, CEOn, Dorian Therapeutics, Mahdi Moqri, Co-Founder and Executive Director, Biomarkers of Aging Consortium, Marco Quarta, Co-Founder and CEO, Rubedo Life Sciences, Payel Sen, Stadtman tenure-track investigator, National Institute of Aging, Peng Leong, Chief Business Officer, BioAge, Priyanka Joshi, Co-founder and Chief Scientific Officer, NeuroAge Therapeutics, Shan Jiang, Senior Scientific Lead, Discovery Bioinformatics, Loxo@Lilly, Suzana Tulac, Director - Translational Development and Project Management, Rejuvenation Biotech, Vittorio Sebastiano, PhD, Founder and Scientific Advisory Board Chair, Turn Bio, Yuxi Lin, Senior Director - Venture Science, Eli Lilly and Co.